ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs

Liang, Guihong; Zhao, Jinlong; Pan, Jianke; Yang, Yuan; Dou, Yaoxing; Yang, Weiyi; Zeng, Lingfeng*; Liu, Jun*广东省人民医院; 广州中医药大学; 5
Journal of Orthopaedic Surgery and Research2023-4-22DOI: 10.1186/s13018-023-03761-1
1被引16阅读
引用收藏
分享

摘要

BackgroundAlthough fisetin may exist widely in many natural herbs, its anti-OP mechanism is still unclear. The aim of this study is to explore the molecular anti-osteoporosis (OP) mechanism of fisetin based on network pharmacology and cell experiments.MethodsThe target of fisetin was extracted by the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The targets of OP were obtained by DisGeNET, GeneCards and the Comparative Toxicogenomics Database, and the targets of fisetin in OP were screened by cross-analysis. The protein-protein interaction (PPI) network was constructed by STRING, and the core targets were obtained. We performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses on common targets via the Database for Annotation, Visualization and Integrated Discovery. Finally, an in vitro cell experiment was used to verify the anti-OP effect and mechanism of fisetin.ResultsThere are 44 targets of fisetin related to the treatment of OP. The PPI results suggest that CTNNB1, CCND1, TP53, JUN, and AKT1 are the core targets. A total of 259 biological process, 57 molecular function and 26 cell component terms were obtained from GO enrichment analysis. The results of KEGG pathway enrichment analysis suggested that fisetin treatment of OP may be related to the Wnt signaling pathway, estrogen signaling pathway, PI3K-Akt signaling pathway and other signaling pathways. In vitro cell experiments showed that fisetin significantly increased the expression levels of ALP, collagen I, osteopontin and RUNX2 in bone marrow mesenchymal stem cells (BMSCs) (p < 0.05). Fisetin also increased the gene expression levels of Wnt3 and beta-catenin (CTNNB1) in BMSCs, which indicates that fisetin can regulate the Wnt/beta-catenin signaling pathway and promote the osteogenic differentiation of BMSCs.ConclusionsFisetin acts on multiple targets and pathways in the treatment of OP; mechanistically, it regulates the Wnt/beta-catenin signaling pathway, which promotes the osteogenic differentiation of BMSCs and maintains bone homeostasis. The results of this study provide a theoretical basis for further study on the complex anti-OP mechanism of fisetin.

学科与关键词

关键词
FisetinChinese traditional medicineOsteoporosisBMSCsMechanismsBone homeostasis
相关
加载中…
  • Mechanism and Experimental Verification of Luteolin for the Treatment of Osteoporosis Based on Network Pharmacology
    Liang, Guihong; Zhao, Jinlong; Dou, Yaoxing; Yang, Yuan; Zhao, Di; Zhou, Zhanpeng; Zhang, Rui; Yang, Weiyi*; Zeng, Lingfeng*Frontiers in Endocrinology, 2022, 13: 866641.被引 9
  • The potential mechanism of Fructus Ligustri Lucidi promoting osteogenetic differentiation of bone marrow mesenchymal stem cells based on network pharmacology, molecular docking and experimental identification
    Kong, Yuanhang; Ma, Xinnan; Zhang, Xin; Wu, Leilei; Chen, Dechun; Su, Bo; Liu, Daqian; Wang, Xintao*Bioengineered, 2022, 13(4): 10640-10653.被引 5
  • Exploration of the Molecular Mechanism of Polygonati Rhizoma in the Treatment of Osteoporosis Based on Network Pharmacology and Molecular Docking
    Zhao, Jinlong; Lin, Fangzheng; Liang, Guihong; Han, Yanhong; Xu, Nanjun; Pan, Jianke; Luo, Minghui; Yang, Weiyi*; Zeng, Lingfeng*Frontiers in Endocrinology, 2022, 12: 815891.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Orthopaedic Surgery and Research
发表日期
2023-04-22
卷期
第 18 卷, 第 1 期
页码
312
DOI
10.1186/s13018-023-03761-1
语言
ENGLISH
成果收录
SCIE

作者

  • L

    Liang, Guihong (第一作者)

    guangdong prov acad chinese med sci · 2 · guangzhou univ chinese med · guangdong prov hosp

  • Z

    Zhao, Jinlong

    2 · guangzhou univ chinese med · guangdong prov acad chinese med sci · guangdong prov hosp

查看全部 8 位作者收起作者
  • P

    Pan, Jianke

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Y

    Yang, Yuan

    guangdong prov acad chinese med sci · 2 · guangzhou univ chinese med · guangdong prov hosp

  • D

    Dou, Yaoxing

    2 · guangzhou univ chinese med · guangdong prov acad chinese med sci · guangdong prov hosp

  • Y

    Yang, Weiyi

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zeng, Lingfeng (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp · guangdong prov acad chinese med sci

  • L

    Liu, Jun (通讯)

    5 · guangzhou univ chinese med · guangdong prov acad chinese med sci

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417